Pfizer Inc.

NYSE:PFE   3:59:58 PM EDT
39.20
+0.14 (+0.37%)
4:00:00 PM EDT: $39.19 -0.01 (-0.01%)
Products

Myovant Sciences And Pfizer Receive FDA Approval For Myfembree, The First Once-Daily Treatment For Heavy Menstrual Bleeding Associated With Uterine Fibroids

Published: 05/26/2021 22:50 GMT
Pfizer Inc. (PFE) - Myovant Sciences and Pfizer Receive FDA Approval for Myfembree®, the First Once-daily Treatment for Heavy Menstrual Bleeding Associated With Uterine Fibroids.
Myovant Sciences Ltd - Myovant and Pfizer Will Jointly Commercialize Myfembree, With Product Availability Expected in June.
Myovant Sciences - Approval is Supported by Efficacy and Safety Data From Phase 3 Liberty 1 and Liberty 2 Studies.